CIENCIASMEDICASNEWS

martes, 27 de octubre de 2026

Do Italian Women Really Have Fewer Mammograms? Roberta Villa, MD

https://www.medscape.com/viewarticle/do-italian-women-really-have-fewer-mammograms-2026a10014j1?src= Sometimes data seem straightforward but can be misleading. I am referring to the data recently published by Eurostat on the availability of equipment and women’s participation in mammography screening within the target age group. According to the bar chart comparing screening rates in 2019 with those in 2024 across EU countries (plus Switzerland, Iceland, and Norway), Italy shows a sharp decline. This negative trend is shared by ten other countries, including Netherlands, France, Ireland, and especially Malta, where the decline can be described as a veritable collapse — from a rate nearing 70% in 2019 to less than 50% in 2024.

6 New GI Studies That Could Shift IBD Care and Colorectal Cancer Screening American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting Highlights: Part 2 David A. Johnson, MD

https://www.medscape.com/viewarticle/6-new-gi-studies-could-shift-ibd-care-and-colorectal-cancer-2026a10013vj?src=

FDA Expands Talazoparib Combo Indication in Prostate Cancer Amy Norton

https://www.medscape.com/viewarticle/fda-expands-talazoparib-combo-indication-prostate-cancer-2026a10014gv?src= The FDA has approved the PARP inhibitor talazoparib (Talzenna, Pfizer) in combination with enzalutamide for the treatment of patients with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. The regimen was first approved by the FDA in 2023, for patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

The Surprising Clues BMI May Miss in Head and Neck Cancer Lisa O’Mary

https://www.medscape.com/viewarticle/surprising-clues-bmi-may-miss-head-and-neck-cancer-2026a10014h5 A recent retrospective cohort study suggested that higher BMI might be associated with improved overall survival in patients with head and neck cancers receiving radiation therapy. These findings reflect what’s known as the obesity paradox — the observation that individuals with cancer or other diseases who have overweight or obesity may actually have lower mortality rates.

Divarasib Beats Approved KRAS Inhibitors in Lung Cancer Frederik Joelving

https://www.medscape.com/viewarticle/divarasib-beats-approved-kras-inhibitors-lung-cancer-2026a10014jm?src= The investigational targeted therapy divarasib extends overall survival in patients with previously treated, advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), outperforming two existing KRAS inhibitors, according to findings from the phase 3 Krascendo 1 trial.

Dual Knockdown CAR T-Cell Therapy Linked to High Response Rates in R/R LBCL

https://www.medscape.com/viewarticle/dual-knockdown-car-t-cell-therapy-linked-high-response-rates-2026a10014jf?src= Anbalcabtagene autoleucel (anbal-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy with dual PD-1 and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) knockdown was associated with high response rates in patients with relapsed or refractory large B-cell lymphoma (LBCL) in a phase 1/2 study. Among 73 evaluable patients, the complete response rate was 67.1%, and those who maintained complete response for at least 6 months had 18-month progression-free survival (PFS) and overall survival (OS) rates of 79.4% and 83.9%, respectively.